New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:38 EDTPETX, ADXSAdvaxis files for USDA product license
Advaxis (ADXS) announced that a product license from the USDA has been filed for ADXS-cHER2, its proprietary Her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other HER2-overexpressing cancers. The filing was submitted by Aratana Therapeutics (PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize ADXS-cHER2 in animals. While the USDA has no specific obligation to respond within a prescribed timeframe, the companies expect a response from the USDA to the filing will occur over the next 12 to 18 months.
News For ADXS;PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
11:06 EDTADXSAduro Biotech selloff an overreaction to adverse event, says Roth Capital
Subscribe for More Information
November 17, 2015
09:18 EDTADXSAdvaxis to receive $1.6M through NJ NOL Program
Advaxis announced the company has received preliminary approval for a $1.8M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2015. The company anticipates it will be able to transfer this credit and receive approximately $1.6M in cash in December.
08:04 EDTPETXStifel to hold a conference
Subscribe for More Information
November 11, 2015
14:56 EDTPETXAratana Therapeutics to host investor day with a conference call hookup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use